SG11201807940XA - Production of antigen-specific t-cells - Google Patents

Production of antigen-specific t-cells

Info

Publication number
SG11201807940XA
SG11201807940XA SG11201807940XA SG11201807940XA SG11201807940XA SG 11201807940X A SG11201807940X A SG 11201807940XA SG 11201807940X A SG11201807940X A SG 11201807940XA SG 11201807940X A SG11201807940X A SG 11201807940XA SG 11201807940X A SG11201807940X A SG 11201807940XA
Authority
SG
Singapore
Prior art keywords
cells
antigen
international
specific
ste
Prior art date
Application number
SG11201807940XA
Inventor
Mathias Oelke
Jose Santos
Sojung Kim
Jonathan Schneck
Alyssa Kosmides
Original Assignee
Neximmune Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neximmune Inc, Univ Johns Hopkins filed Critical Neximmune Inc
Publication of SG11201807940XA publication Critical patent/SG11201807940XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

International Patent Classification: A61K 39/39 (2006.01) A61K 35/17 (2015.01) A61K 47/48 (2006.01) C07K 14/725 (2006.01) (21) International Application Number: PCT/US2017/022663 (22) International Filing Date: 16 March 2017 (16.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/309,234 16 March 2016 (16.03.2016) US (71) Applicants: NEXIMMUNE, INC. [US/US]; 9119 Gaither Road, Ste A, Gaithersburg, MD 20877 (US). THE JOHNS HOPKINS UNIVERSITY [US/US]; 3400 N. Charles Street, Baltimore, MD 21218 (US). (72) Inventors: OELKE, Mathias; Neximmune, Inc., 9119 Gaither Road, Ste A, Gaithersburg, MD 20877 (US). SAN- TOS, Jose, Luis; Neximmune, Inc., 9119 Gaither Road, Ste A, Gaithersburg, MD 20877 (US). KIM, Sojung; Nex- immune, Inc., 9119 Gaither Road, Ste A, Gaithersburg, MD 20877 (US). SCHNECK, Jonathan; The Johns Hop- kins University, 3400 N. Charles Street, Baltimore, MD 21218 (US). KOSMIDES, Alyssa; The Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218 (US). (74) Agents: HAYMAN, Mark, L. et al.; Morgan, Lewis & Bockius LLP, 1111 Pennsylvania Avenue, NW, Washing- ton, DC 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, CF, CG, CI, CM, GA, GN, GQ, BJ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) [Continued on next page] (54) Title: PRODUCTION OF ANTIGEN-SPECIFIC T-CELLS FIG. 1 100nm DEXTRAN ANTI-BIOTIN COAT IRON OXIDE CORE SIGNAL 1 MHC-Ig DIMER- BIOTIN SIGNAL 2 CD28- BIOTIN 25 co g 20 15 10 5 2C T CELLS O O PMEL T CELLS CD8 CELL ACTIVATION ANTIGEN CD8 CELL PRESENTING CELL MHC-1 TCR SIGNAL 1 SIGNAL 2 CD80ICD88 CD28 ANTI-BIOTIN IRON-DEXTRAN NAN OPARTICL E W O 20 17 / 16 109 2 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/161092 Al 21 September 2017 (21.09.2017) WIPO I PCT (57) : The invention in various aspects provides for magnetic enrichment and/or expansion of antigen-specific T cells, al- lowing for identification and characterization of antigen-specific T cells and their T cell receptors (TCRs) for therapeutic and/or dia- gnostic purposes, as well as providing for production of antigen-specific engineered T cells for therapy. Incubation of paramagnetic nano-aAPCs in the presence of a magnetic field, either during enrichment and/or expansion steps, activates T cells through magnetic clustering of paramagnetic particles on the T cell surface. 1111111111111101110101011111010111110 01111111101011011101011111111111110111111 WO 2017/161092 Al 1111111111111101110111111111111111110111011111111111111111111111011111111111110111111 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201807940XA 2016-03-16 2017-03-16 Production of antigen-specific t-cells SG11201807940XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662309234P 2016-03-16 2016-03-16
PCT/US2017/022663 WO2017161092A1 (en) 2016-03-16 2017-03-16 Production of antigen-specific t-cells

Publications (1)

Publication Number Publication Date
SG11201807940XA true SG11201807940XA (en) 2018-10-30

Family

ID=59850933

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201807940XA SG11201807940XA (en) 2016-03-16 2017-03-16 Production of antigen-specific t-cells
SG10202008210XA SG10202008210XA (en) 2016-03-16 2017-03-16 Production of antigen-specific t-cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202008210XA SG10202008210XA (en) 2016-03-16 2017-03-16 Production of antigen-specific t-cells

Country Status (11)

Country Link
US (2) US20200291381A1 (en)
EP (1) EP3445399A4 (en)
JP (1) JP7016098B2 (en)
KR (1) KR102470979B1 (en)
CN (1) CN109475620A (en)
AU (1) AU2017233035B2 (en)
CA (1) CA3017615A1 (en)
IL (1) IL261710A (en)
RU (2) RU2745319C2 (en)
SG (2) SG11201807940XA (en)
WO (1) WO2017161092A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45491A (en) * 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
BR112020005552A2 (en) * 2017-09-20 2020-10-27 Neximmune, Inc. cell compositions comprising antigen-specific t cells for adoptive therapy
CA3077085A1 (en) 2017-10-06 2019-04-11 Oncotherapy Science, Inc. Screening of t lymphocytes for cancer-specific antigens
JP2021527419A (en) * 2018-06-20 2021-10-14 ダンマークス テクニスク ユニバーシテットＤａｎｍａｒｋｓ Ｔｅｋｎｉｓｋｅ Ｕｎｉｖｅｒｓｉｔｅｔ Scaffold with stabilized MHC molecules for immune cell manipulation
CA3110706A1 (en) * 2018-09-19 2020-03-26 FUJIFILM Cellular Dynamics, Inc. Protein l for activation and expansion of chimeric antigen receptor-modified immune cells
CN109136276A (en) * 2018-09-30 2019-01-04 北京鼎成肽源生物技术有限公司 A kind of construction method of RFFT2 cell
US20200188435A1 (en) * 2018-11-08 2020-06-18 Nexlmmune, Inc. T cell compositions with improved phenotypic properties
WO2021173847A1 (en) * 2020-02-27 2021-09-02 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Cobra1/nelf-b as a booster for efficacy of cd8+ t cell-based therapy
WO2021262846A1 (en) * 2020-06-26 2021-12-30 The Johns Hopkins University Adaptive nanoparticle platforms for high throughput expansion and detection of antigen-specific t cells
US20240066062A1 (en) * 2020-12-11 2024-02-29 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2023060217A1 (en) * 2021-10-08 2023-04-13 Baylor College Of Medicine Transgenic t cell receptors targeting neoantigens for diagnosis, prevention, and/or treatment of hematological cancers
WO2023144275A1 (en) * 2022-01-28 2023-08-03 Katholieke Universiteit Leuven Actuation of organoids by magnetic nanoparticles
DE102022132082B4 (en) 2022-12-02 2024-08-08 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Process for the preparation of immunocompetent cells genetically transfected and loaded with nanoparticles and/or a cytotoxic substance, as well as immunocompetent cells and medical composition.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2311920C2 (en) * 2000-09-20 2007-12-10 Корикса Корпорейшн Compositions and methods for treating and predicting pulmonary cancer
AU2003300359A1 (en) * 2003-05-08 2004-12-13 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
AT503861B1 (en) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING T-CELL RECEPTORS
US20120128656A1 (en) * 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
CN102168066A (en) * 2011-01-31 2011-08-31 浙江大学 Method for in vitro induction of specific cytotoxic T lymphocytes of hepatitis B virus (HBV)
KR20210149195A (en) * 2012-07-13 2021-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Methods of assessing the suitability of transduced T cells for administration
KR102164405B1 (en) * 2013-03-14 2020-10-12 더 존스 홉킨스 유니버시티 Nanoscale artificial antigen presenting cells
US11807675B2 (en) * 2013-10-03 2023-11-07 The University Of Maryland, Baltimore Nanoparticle based artificial antigen presenting cell mediated activation of NKT cells
US10066265B2 (en) * 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
KR20160016725A (en) * 2014-08-05 2016-02-15 주식회사 유영제약 CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS TARGETING IL13Rα2 ON TUMORS

Also Published As

Publication number Publication date
AU2017233035A1 (en) 2018-11-01
SG10202008210XA (en) 2020-10-29
EP3445399A1 (en) 2019-02-27
AU2017233035B2 (en) 2021-08-05
IL261710A (en) 2018-10-31
KR20190026645A (en) 2019-03-13
RU2018136203A3 (en) 2020-06-22
JP2019513412A (en) 2019-05-30
CA3017615A1 (en) 2017-09-21
RU2018136203A (en) 2020-04-16
US20230332131A1 (en) 2023-10-19
WO2017161092A1 (en) 2017-09-21
CN109475620A (en) 2019-03-15
RU2745319C2 (en) 2021-03-23
US20200291381A1 (en) 2020-09-17
RU2021107053A (en) 2021-08-24
KR102470979B1 (en) 2022-11-24
JP7016098B2 (en) 2022-02-21
EP3445399A4 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
SG11201807940XA (en) Production of antigen-specific t-cells
SG11201805072PA (en) Nicotine powder delivery system
SG11201909949XA (en) Targeted immunotolerance
SG11201808633RA (en) Anti-human vista antibodies and use thereof
SG11201809330TA (en) Item handling system, method and apparatus therefor
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201805137XA (en) Virus encoding an anti-tcr-complex antibody or fragment
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201809617RA (en) Intracellular delivery of biomolecules to induce tolerance
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805449PA (en) Methods of making chimeric antigen receptor -expressing cells
SG11201803701YA (en) Methods and compositions for gene editing in hematopoietic stem cells
SG11201805507UA (en) Retractable heat source for aerosol generating article
SG11201807771UA (en) Multiple dispersion generator e-vaping device
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201908127WA (en) Method for producing multispecific antibodies
SG11201806401YA (en) G protein-coupled receptor (gpcr) modulation by imipridones
SG11201909501TA (en) Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro
SG11201805204WA (en) Nicotine particle capsule
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201807041PA (en) Improved preparations of adult liver progenitor cells